High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma

CONCLUSION: Dasatinib and other SFK inhibitors represent novel candidate treatments for LGSOC and demonstrate synergy with trametinib. Disulfiram represents an additional treatment strategy worthy of investigation.PMID:38582027 | DOI:10.1016/j.ygyno.2024.03.029

Source: Gynecologic Oncology - April 6, 2024 Category: Cancer & Oncology Authors: Robert L Hollis Richard Elliott John C Dawson Narthana Ilenkovan Rosie M Matthews Lorna J Stillie Ailsa J Oswald Hannah Kim Marta Llaurado Fernandez Michael Churchman Joanna M Porter Patricia Roxburgh Asier Unciti-Broceta David M Gershenson C Simon Herrin Source Type: research